Abstract:Doxorubicin (DOX) is one of the most commonly used anticancer drugs; however, its clinical application is greatly limited due to its toxicity and chemotherapy resistance. The delivery of DOX by liposomes (Lipos) can improve the blood circulation time in vivo and reduce toxic side effects, but the drug's accumulation in the tumor is often insufficient for effective treatment. In this study, we present a calcium cross-linked liposome gel for the encapsulation of DOX, demonstrating its superior long-term release capabilities compared to conventional Lipos. By leveraging this enhanced long-term release, we can enhance drug accumulation within tumors, ultimately leading to improved antitumor efficacy. Lipos were prepared using the thin-film dispersion method in this study. We utilized the ion-responsiveness of glutathione-gelatin (GSH-GG) to form the gel outside the Lipos and named the nanoparticles coated with GSH-GG on the outside of Lipos as Lipos@GSH-GG. The average size of Lipos@GSH-GG was around 342.9 nm, with a negative charge of -25.6 mV. The in vitro experiments revealed that Lipos@GSH-GG exhibited excellent biocompatibility and slower drug release compared to conventional Lipos. Further analysis of cellular uptake and cytotoxicity demonstrated that Lipos@GSH-GG loading DOX (DOX&Lipos@GSH-GG) exhibited superior long-term release effects and lower toxic side effects compared to Lipos loading DOX (DOX&Lipos). Additionally, the findings regarding the long-term release effect in vivo and the tumor accumulation within tumor-bearing mice of Lipos@GSH-GG suggested that, compared to Lipos, it demonstrated superior long-term release capabilities and achieved greater drug accumulation within tumors. In vivo antitumor efficacy experiments showed that DOX&Lipos@GSH-GG demonstrated superior antitumor efficacy to DOX&Lipos. Our study highlights Lipos@GSH-GG as a promising nanocarrier with the potential to enhance efficacy and safety by means of long-term release effects and may offer an alternative approach for effective antitumor therapy in the future.

Cerasomal doxorubicin with long-term storage stability and controllable sustained release

Organic–inorganic Nanovesicles for Doxorubicin Storage and Release

In Situ Protein-Templated Porous Protein-Hydroxylapatite Nanocomposite Microspheres for Ph-Dependent Sustained Anticancer Drug Release

Redox Responsive Liposomal Nanohybrid Cerasomes for Intracellular Drug Delivery.

Design and synthesis of lipidic organoalkoxysilanes for the self-assembly of liposomal nanohybrid cerasomes with controlled drug release properties.

Stabilized Liposomal Nanohybrid Cerasomes for Drug Delivery Applications

Safety evaluation of liposomal nanohybrid cerasomes and their application in the release of 10-hydroxycamptothecin

Paclitaxel controlled release system based on novel cerasome

Stabilized Magnetic Cerasomes for Drug Delivery.

Highly uniform and stable cerasomal microcapsule with good biocompatibility for drug delivery.

Ultrasound Triggered Local Sequential Reactive Oxygen Species and Nitric Oxide Release for Enhanced Cerasomal Drug Delivery

Efficient Energy Transfer and Controlled Drug Release in Highly Stable Novel Nanoliposomes

Recent advances in liposomal nanohybrid cerasomes as promising drug nanocarriers.

Preparation of Liposome Gel by Calcium Cross-Linking Induces the Long-Term Release of DOX to Improve the Antitumor Effect

Robust, Tumor-Homing and Redox-Sensitive Polymersomal Doxorubicin: A Superior Alternative to Doxil and Caelyx?

Freeze-drying of Liposomal Nanohybrid Cerasomes with Cryoprotectants: in Vitro and in Vivo Evaluation

Liposomal Nanohybrid Cerasomes for Mitochondria-Targeted Drug Delivery

Balancing the Stability and Drug Release of Polymer Micelles by the Coordination of Dual-Sensitive Cleavable Bonds in Cross-Linked Core.

Doxorubicin-loading core-shell pectin nanocell: A novel nanovehicle for anticancer agent delivery with multidrug resistance reversal

Stable Cerasomes for Simultaneous Drug Delivery and Magnetic Resonance Imaging.

Reduction/temperature/pH Multi-Stimuli Responsive Core Cross-Linked Polypeptide Hybrid Micelles for Triggered and Intracellular Drug Release.